CXXB750A12201 (Recruiting)

a multi center, randomized, double-blind placebo controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety and tolerability of XXB750 in patients with heart failure